Study of Treatment Used for Migraine Headaches (MK-0974-076)

Study Overview
=================
Brief Summary
-----------------
This study will describe the reasons for triptan utilization patterns (continuation and discontinuation) in triptan-naïve participants and assess the stability of treatment utilization patterns over time according to standard medical guidelines or clinical practice standards of the investigating physician.

Detailed Description
-----------------
After study start, the Protocol was amended to clarifiy that the first triptan prescription must have been received by the participant within a time window of 3 months (± 2 weeks) prior to the participant being identified by the Investigator, and could be enrolled into the study within 6 months of taking the prescribed triptan medication for the first time and that use of a sample triptan would not disqualify a participant as long as the sample was of the same triptan that was eventually prescribed.

Official Title
-----------------
Migraine Attack Study of Treatment, Efficacy and Resource Use (MASTER) - McKesson Substudy (MK-0974-076)

Conditions
-----------------
Migraine

Intervention / Treatment
-----------------
* Drug: Statin Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: At least 18 years of age in the United States at the time of consent Physician-diagnosed migraine with or without aura At least two and up to a maximum of 8 moderate to severe migraine attacks during the 30 days prior to screening Initial triptan prescription 3 months (± 2 weeks) prior to being identified as eligible for this study, and triptan-naïve before that initial prescription Used triptan medication at least once within 6 months prior to the date of informed consent for screening Internet access and able to complete online surveys via electronic data entry Exclusion criteria: Treated with triptans prior to this study In active litigation and compensation issues including disability dispute cases with a Government agency Participation in a clinical trial within the last 90 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants Enrolled in Protocol Version (V)1.1<br>Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V1.1 of this study. | Drug: Statin Therapy<br>* Investigator's choice of any statin.<br>|
| Participants Enrolled in Protocol V2<br>Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V2 of this study. | Drug: Statin Therapy<br>* Investigator's choice of any statin.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants Using a Triptan for Migraine Attacks | Participants reported information online. For this measure, the number of participants who used at least one dose of any newly prescribed triptan for the first time in response to a migraine attack were counted. | Up to 3 months | 
| Number of Participants Continuing Triptan Therapy | Participants reported information online. For this measure, the number of participants who continued to use a triptan after the first migraine attack were counted; switching from one triptan to another was considered continued use. | Up to 3 monoths | 
| Main Reason for Stopping Triptan Use |  | Up to 3 months |